武汉科前生物股份有限公司2025 年半年度报告 公司代码：688526 公司简称：科前生物 武汉科前生物股份有限公司 武汉科前生物股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 报告期内不存在对公司生产经营产生实质性影响的重大风险，公司已在报告中详细描述可能 存在的相关风险，敬请查阅"第三节管理层讨论与分析"之"四、风险因素"部分内容，敬请投 资者注意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人陈慕琳、主管会计工作负责人钟鸣及会计机构负责人（会计主管人员）陈婵姹 声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的公司未来经营计划、发展战略、预测等前瞻性陈述不构成本公司对投资者的 实质承诺，敬请 ...

Core Insights - The global animal vaccine industry has seen continuous growth, with a market size exceeding $13.5 billion in 2023 and a compound annual growth rate (CAGR) of 10.10% over the past five years, indicating increasing emphasis on disease prevention in animals and food safety [1][15] - The quality of animal vaccine products is directly linked to the safety of livestock products and, consequently, public food safety, leading to significant national attention and planning for the industry [1] - Local governments are actively promoting the development of animal vaccine enterprises, focusing on attracting advanced technologies and management practices to enhance local industry standards [1] Industry Overview - The animal vaccine market is projected to reach $3.8 billion by 2029, driven by the commercialization of vaccines for diseases like African swine fever and increasing pet vaccination awareness among residents [15] - In 2023, North America accounted for approximately 45% of the global animal vaccine market, making it the largest regional market [9] Key Players - Qingdao Yebio Bioengineering Co., Ltd. is a leading player in the domestic animal vaccine industry, with 87 vaccine products, the highest in the market, and an annual R&D investment of about 9% of its sales [7] - Other notable companies in the industry include China Animal Husbandry Industry Co., Ltd. and Tianjin Reap Bio-Technology Co., Ltd., both of which have significant revenue from animal vaccine operations [7][2] Regulatory and Developmental Support - The Chinese government has included animal vaccines in its "14th Five-Year Plan," highlighting the importance of the industry and encouraging local governments to support enterprise development [1] - The industry is characterized by a focus on innovation, with many companies establishing national key laboratories and innovation platforms to advance vaccine research and development [7]

Core Viewpoint - The company, Pulaike Biological Engineering Co., Ltd., has released its 2024 annual report summary, highlighting its financial performance, profit distribution plan, and the current state of the veterinary medicine industry in China. Company Overview - Pulaike operates in the veterinary medicine manufacturing sector, providing essential support for high-quality development in livestock farming and pet health management [5]. - The company focuses on the research, production, and sales of veterinary biological products, chemical drugs, and traditional Chinese veterinary medicine, with over 80 biological products and 200 chemical drugs in its portfolio [17][18]. Industry Situation Industry Scale - In 2023, China's veterinary medicine production enterprises achieved sales of 69.651 billion yuan, with a gross profit of 21.297 billion yuan. The industry has shown an overall upward trend over the past decade, with a compound annual growth rate of 6.16% [6]. Competitive Landscape - The industry consists of 1,620 veterinary medicine production enterprises, primarily medium and small-sized. Large enterprises account for 15.25% of biological product companies and 4.02% of chemical drug companies, indicating a stable industry concentration [7]. Development Trends - The veterinary medicine industry aims to provide high-quality products and services for livestock and pet owners. Companies with core competitiveness in technology innovation, product quality, market expansion, and comprehensive service capabilities will thrive in a highly competitive market [9]. Regulatory Policies - New regulations regarding veterinary drug registration and animal disease prevention have been introduced, aiming to enhance the authenticity and standardization of registration materials and improve disease control measures [10][11]. Financial Performance - For the fiscal year 2024, the company reported a net profit of 92.8065 million yuan, with a proposed cash dividend of 4 yuan per 10 shares, amounting to an estimated total distribution of 136.7677 million yuan [27][26]. Shareholder Information - The company has a total share capital of 346,062,273 shares, with 4,142,900 shares repurchased and not participating in the profit distribution [27][28]. Cash Management - The company plans to use up to 650 million yuan of idle funds for cash management, focusing on safe and liquid short-term investment products [34][35].